Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?
Identifieur interne : 000C54 ( Main/Exploration ); précédent : 000C53; suivant : 000C55Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?
Auteurs : Richard D. Sontheimer [États-Unis]Source :
- Annals of translational medicine [ 2305-5839 ] ; 2018.
Abstract
It is now widely accepted that long-term aminoquinoline antimalarial therapy with hydroxychloroquine (HCQ) can mitigate one of the most important comorbidities of systemic lupus erythematosus (LE)-atherosclerotic cardiovascular disease (ASCVD). Increasing evidence suggests that idiopathic inflammatory myopathy (IIM) patients have a risk for ASCVD comorbidity that is similar to that of systemic LE. I would like to explore the primary hypothesis that long-term HCQ therapy could provide those with IIM, especially dermatomyositis (DM) patients, an ASCVD comorbidity benefit similar to that of systemic LE. In addition, while HCQ is known to have clinical benefits for the cutaneous manifestations of DM, I would also like to explore the secondary hypothesis that HCQ might have steroid-sparing effects on one or more of the systemic manifestations of DM.
DOI: 10.21037/atm.2018.03.05
PubMed: 29862243
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000103
- to stream PubMed, to step Curation: 000103
- to stream PubMed, to step Checkpoint: 000127
- to stream Ncbi, to step Merge: 000450
- to stream Ncbi, to step Curation: 000450
- to stream Ncbi, to step Checkpoint: 000450
- to stream Main, to step Merge: 000C54
- to stream Main, to step Curation: 000C54
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?</title><author><name sortKey="Sontheimer, Richard D" sort="Sontheimer, Richard D" uniqKey="Sontheimer R" first="Richard D" last="Sontheimer">Richard D. Sontheimer</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29862243</idno><idno type="pmid">29862243</idno><idno type="doi">10.21037/atm.2018.03.05</idno><idno type="wicri:Area/PubMed/Corpus">000103</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000103</idno><idno type="wicri:Area/PubMed/Curation">000103</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000103</idno><idno type="wicri:Area/PubMed/Checkpoint">000127</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000127</idno><idno type="wicri:Area/Ncbi/Merge">000450</idno><idno type="wicri:Area/Ncbi/Curation">000450</idno><idno type="wicri:Area/Ncbi/Checkpoint">000450</idno><idno type="wicri:doubleKey">2305-5839:2018:Sontheimer R:aminoquinoline:antimalarial:therapy</idno><idno type="wicri:Area/Main/Merge">000C54</idno><idno type="wicri:Area/Main/Curation">000C54</idno><idno type="wicri:Area/Main/Exploration">000C54</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?</title><author><name sortKey="Sontheimer, Richard D" sort="Sontheimer, Richard D" uniqKey="Sontheimer R" first="Richard D" last="Sontheimer">Richard D. Sontheimer</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author></analytic><series><title level="j">Annals of translational medicine</title><idno type="ISSN">2305-5839</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It is now widely accepted that long-term aminoquinoline antimalarial therapy with hydroxychloroquine (HCQ) can mitigate one of the most important comorbidities of systemic lupus erythematosus (LE)-atherosclerotic cardiovascular disease (ASCVD). Increasing evidence suggests that idiopathic inflammatory myopathy (IIM) patients have a risk for ASCVD comorbidity that is similar to that of systemic LE. I would like to explore the primary hypothesis that long-term HCQ therapy could provide those with IIM, especially dermatomyositis (DM) patients, an ASCVD comorbidity benefit similar to that of systemic LE. In addition, while HCQ is known to have clinical benefits for the cutaneous manifestations of DM, I would also like to explore the secondary hypothesis that HCQ might have steroid-sparing effects on one or more of the systemic manifestations of DM.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Utah</li></region></list><tree><country name="États-Unis"><region name="Utah"><name sortKey="Sontheimer, Richard D" sort="Sontheimer, Richard D" uniqKey="Sontheimer R" first="Richard D" last="Sontheimer">Richard D. Sontheimer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29862243
|texte= Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29862243" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |